Company: ARTL
Filing Date: 2025-08-07
Form Type: DEF 14A
Source: 0001640334-25-001376
Chunk: 11

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-08-07
Form: DEF 14A
Chunk 11
---
isable within 60 days of July 25, 2025.                                                                                                                                                                     |

| 7 |

<div align='center'>PROPOSAL 1

TO APPROVE AN AMENDMENT TO OUR ARTICLES OF INCORPORATION, AS AMENDED, TO INCREASE THE AUTHORIZED NUMBER OF SHARES OF OUR COMMON STOCK FROM 8,333,333 TO 500,000,000</div>

General

Our Board has unanimously adopted a resolution approving an amendment to our Articles to increase the authorized number of shares of Common Stock from 8,333,333 shares to 500,000,000 shares (the “Increase Shares Amendment”). Approval of the Increase Shares Amendment will grant the Board the authority, without further action by the stockholders, to carry out the amendment to the Articles after the date of stockholder approval for the Increase Shares Amendment.

Our Board has determined that it is advisable to increase the authorized number of shares of our Common Stock from 8,333,333 to 500,000,000 and recommends that our stockholders approve the Increase Shares Amendment to effect the proposed increase. The form of the proposed amendment to our Articles is attached to this Proxy Statement as . If approved by our stockholders, we intend to file the Increase Shares Amendment, in substantially the form attached hereto as, with the Secretary of State of Nevada as soon as practicable following the Special Meeting, and such amendment will be effective upon filing. If this proposal is not approved by our stockholders, our Articles will continue as currently in effect.

Purpose of the Increase in Authorized Shares

As of July 25, 2025, we had 8,333,333 authorized shares of Common Stock of which 704,425 shares were issued and outstanding. Of the remaining 7,628,908 authorized shares of Common Stock, 899,744 shares are reserved for issuance upon the exercise of issued and outstanding warrants, 128,976 shares are reserved for issuance upon the exercise of issued and outstanding equity awards and 206,588 shares are reserved for future issuance under our existing stock incentive plans.

On May 22, 2025, we received a notice (the “May Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying us that we are not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In our Quarterly Report on Form 10